Vivani Medical, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Vivani enrolled all 20 participants in SLIM-1 Phase 1 trial of NPM-139 (semaglutide implant) with top-line data expected November 2026. The company signed a non-exclusive evaluation agreement with Novo Nordisk for NPM-139 and its NanoPortal technology platform (no exclusivity clauses). Separately, Vivani's subsidiary Cortigent agreed to merge with Nasdaq-listed ClearOne, expected to complete Q3 2026, spinning Cortigent into an independent public company under ticker CRGT. Cash position: $20.8M as of June 30, 2026 (vs. $17.6M Dec 31, 2025); six-month net loss $13.2M; Q2 net loss $6.4M.
Why this rating
Phase 1 completion and Novo partnership validate NPM-139 pipeline; Cortigent spinoff reduces burn and refocuses parent. Novo deal is non-exclusive (limits upside). $20.8M cash runway material for $45.9M market cap company; burn ~$13M/6mo suggests <2-year horizon without added funding.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.